There was a significant increase in ASCT2 expression in tumour samples compared to normal (pairwise t‐test, p = 0.025), with 24/36 patients showing increased tumour ASCT2 levels compared to patient‐matched normal prostate tissue (χ2 test, p = 0.046). This evidence concerns the gene SLC1A5 and neoplasm.